Identifying and Validating Biomarkers to Develop Truly Disease Modifying Therapeutics for Alzheimer’s Disease
The Biomarkers for Alzheimer’s Disease Summit is the industry’s only digital forum dedicated to sharing innovations in identifying new novel biomarkers and solving the challenges of developing clinically validated biomarkers for the earlier detection and diagnosis of Alzheimer’s Disease that are predictive of outcome measures and accurately reflect a therapeutic effect on target engagement!
Back for its 2nd year there will be a continued emphasis on looking beyond amyloid and tau and diversifying the biomarker landscape, this industry-defining meeting delves into blood-based biomarkers, neuroinflammatory markers and ample sharing of industry innovations in identifying novel biomarkers. Through open reflections and sharing competitive knowledge, this meeting will enable drug developers to scale the hurdles preventing the identification and validation of biomarkers to accelerate the development of disease modifying therapeutics for Alzheimer’s including:
- Utilizing Animal Models & Their Translational Models
- Advancements in Patient Stratification & Identification
- Updates in Neurodegenerative Disease Modelling
- Presenting Biomarker Efficacy & Clinical Validation
For the full program, download the brochure here!
The Biomarkers for Alzheimer’s Disease Summit is your opportunity to discuss in-depth the cutting-edge advances in biomarker science, convey lessons learned and network to build long lasting partnerships.
World-Class Speaker Faculty Includes:
President & Founder
Associate Director & Head of Translational Genetics
Founder & Chief Executive Officer
Head of Translational Medicine
Vice President of Translational Biology
Head of Biomarkers
Co-Chief Scientific Officer
The Michael J Fox Foundation
Assistant Director – Scientific Affairs
Alzheimer’s Drug Discover Foundation
Director of Diagnostic Development & Translational Medicine Diagnostic Development, Translational Medicine & Diagnostics